Liver argininosuccinate synthase binds to bacterial lipopolysaccharides and lipid A and inactivates their biological activities

Abstract

The liver is known to clear and detoxify circulating lipopolysaccharide (LPS). To characterize the molecules involved in this process in the liver, we attempted to purify mouse liver protein(s) that can interact with lipid A, a biologically active portion of LPS. By partially purifying the inactivating activity against a synthetic lipid A analog, we observed the enrichment of a 45-kDa protein in the active fractions. The internal amino acid sequences of the protein were identical with those of argininosuccinate synthase (EC 6.3.4.5). To examine whether argininosuccinate synthase can interact with lipid A, we purified the enzyme from mouse liver and found the co-elevation of the specific enzyme activity and specific lipid A-inactivating activity, indicating that argininosuccinate synthase is the major lipid A-interacting protein in liver. Argininosuccinate synthase also inhibited the biological activities (macrophage activation and Limulus test) of natural lipid A and rough-type LPS but not smooth-type LPS. The enzyme activity was inhibited by lipid A and rough-type LPS and also by smooth-type LPS. Native gel electrophoresis of a mixture of argininosuccinate synthase and LPS and immunoprecipitation of a mixture of argininosuccinate synthase and [³H]-LPS with anti-argininosuccinate synthase antiserum showed that argininosuccinate synthase stably bound lipid A and LPS. These findings, together, indicate that argininosuccinate synthase can effectively bind LPS in the liver.

Keywords

Argininosuccinate synthase clearance endotoxin lipid A liver

References

Nowotny A. Review of molecular requirements of endotoxic reactions. Rev Infect Dis 1987; 9: 503—511.

Morrison DC , Ryan JL Bacterial endotoxin and host immune response. Adv Immunol 1983; 28: 293—452.

Macintire DK , Bellhorn TL Bacterial translocation: clinical implications and prevention. Vet Clin North Am Small Anim Pract 2002; 32: 1165—1178.

Lichtman SM Bacterial translocation in humans. J Pediatr Gastroenterol Nutr 2001; 33: 1—10.

Knapp S. , Branger J. , van der Poll T. Advances in research of the inflammatory response: the importance of Toll-like receptors. Wien Med Wochenschr 2002; 152: 552—554.

Muroi M. , Ohnishi T. , Tanamoto K. Regions of the mouse CD14 molecule required for Toll-like receptor 2- and 4-mediated activation of NF-κB. J Biol Chem 2002; 277: 42372—42379.

Gutsmann T. , Muller M. , Carroll SF et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69: 6942—6950.

Thomas CJ , Kapoor M. , Sharma S. et al. Evidence of a trimolecular complex involving LPS, LPS binding protein and soluble CD14 as an effector of LPS response. FEBS Lett 2002; 531: 184—188.

Little RG , Kelner DN , Lim E. , Burke DJ , Conlon PJ Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J Biol Chem 1994; 269: 1865—1872.

10.

Larrick JW , Hirata M. , Zheng H. et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994; 152: 231—240.

11.

Elass-Rochard E. , Roseanu A. , Legrand D. et al. Lactoferrin-lipopolysaccharide interaction involvement of the 28—34 loop region of human lactoferrin in the high affinity binding to Escherichia coli O55:B5 lipopolysaccharide. Biochem J 1995; 312: 839—845.

12.

de Haas CJ , van der Tol ME , Van Kessel KP , Verhoef J. , Van Strijp JA A synthetic lipopolysaccharide-binding peptide based on amino acids 27—39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood. J Immunol 1998; 161: 3607—3615.

13.

Yang H. , Wang H. , Bernik TR et al. Globin attenuates the innate immune response to endotoxin. Shock 2002; 17: 485—490.

14.

Lehrer RI , Ganz T. Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Ann NY Acad Sci 1996 ; 797: 228—239.

15.

Zanetti M. , Gennaro R. , Romeo D. The cathelicidin family of antimicrobial peptide precursors: a component of the oxygen-independent defense mechanisms of neutrophils. Ann NY Acad Sci 1997; 832: 147—162.

16.

Sano H. , Chiba H. , Iwaki D. , Sohma H. , Voelker DR , Kuroki Y. Surfactant proteins A and D bind CD14 by different mechanisms. J Biol Chem 2000; 275: 22442—22451.

17.

Kitchens RL , Munford RS CD-14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS. J Immunol 1998 ; 160: 1920—1928.

18.

Gegner JA , Ulevitch RJ , Tobias PS Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 1995; 270; 5320—5325.

19.

Hewett JA , Roth RA Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev 1993; 45: 382—411.

20.

Harris HW , Grunfeld C. , Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91: 1028—1034.

21.

Harris HW , Brady SE , Rapp JH Hepatic endosomal trafficking of lipoprotein-bound endotoxin in rats. Surg Res 2002; 106: 188—195.

22.

Reynolds JV , Murchan P. , Leonard N. , Clarke P. , Keane FB , Tanner WA Gut barrier failure in experimental obstructive jaundice. J Surg Res 1996; 62: 11—16.

23.

Kakkos SK , Kirkilesis J. , Scopa CD , Arvaniti A. , Alexandrides T. , Vagianos CE Nonabsorbable antibiotics reduce bacterial and endotoxin translocation in hepatectomised rats. HPB Surg 1997; 10: 283—289.

24.

Hori Y. , Takeyama Y. , Ueda T. , Nishikawa J. , Yamamoto M. , Saitoh Y. Impaired transport of lipopolysaccharide across the hepatocytes in rats with cerulein-induced experimental pancreatitis. Pancreas 1998; 16: 148—153.

25.

Satoh M. , Matsumura T. , Nakamoto M. , Yamazaki M. Inhibition of TNF-triggering activity of lipopolysaccharide by a proteinaceous factor from normal mouse liver extract. J Immunol 1995; 155: 877—885.

26.

Saheki T. , Sase M. , Nakano K. , Azuma F. , Katsunuma T. Some properties of argininosuccinate synthetase purified from human liver and a comparison with the rat liver enzyme. J Biochem 1983; 93; 1531—1537.

27.

Xie L. , Gross SS Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. J Biol Chem 1997; 272: 16624—16630.

28.

Laemmli UK Cleavage of structural proteins during the assembly of the bead of bacteriophage T4. Nature 1970; 227: 680—685.

29.

Schëgger HJ , von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of protein in the range from 1 to 100 kDa. Anal Biochem 1987; 166: 368—379.

30.

Surh LC , Beaudet AL , O'Brien WE. Molecular characterization of the murine argininosuccinate synthetase locus. Gene 1991; 99: 181—189.

31.

Fengsrud M. , Raiborg C. , Berg TO et al. Autophagosomeassociated variant isoforms of cytosolic enzymes. Biochem J 2000; 352: 773—781.

32.

Saheki T. , Kusumi T. , Takada S. , Katsunuma T. Crystallization and some properties of argininosuccinate synthase from rat liver. FEBS Lett 1975; 58: 314—317.

33.

Rochovansky O. , Kodowaki H. , Ratner S. Biosynthesis of urea. Molecular and regulatory properties of crystalline argininosuccinate synthetase. J Biol Chem 1977; 252: 5287—5294.

34.

Imamura Y. , Kobayashi K. , Yamashita T. et al. Clinical application of enzyme immunoassay in the analysis of citrullinemia. Clin Chim Acta 1987; 164: 201—208.

35.

Homma JY , Matsuura M. , Kanegasaki S. et al. Structural requirement of lipid A responsible for the functions: a study with chemically synthesized lipid A and its analogues. J Biochem 1985; 98: 395—406.

36.

Zhang X. , Morrison DC Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. J Leukoc Biol 1993; 54: 444—450.

37.

Kusunoki T. , Hailman E. , Juan TS , Lichenstein HS , Wright SD Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995; 182: 1673—1682.

38.

Takada S. , Kusumi T. , Saheki T. , Tsuda M. , Katsunuma T. Studies of rat liver argininosuccinate synthetase. The presence of three forms, and their physicochemical, catalytic, and immunochemical properties. J Biochem 1979; 86: 1353—1359.

39.

Iovine N. , Eastvold J. , Elsbach P. , Weiss JP , Gioannini TL The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein—lipopolysaccharide complexes. J Biol Chem 2002; 277: 7970—7978.

40.

Lei M-G. , Stimpson SA , Morrison DC Specific endotoxic lipopolysaccharide-binding receptors on murine splenocytes. III. Binding specificity and characterization. J Immunol 1991; 147: 1925—1932.

41.

Mueller M. , Lindner B. , Kusumoto S. et al. Aggregates are the biologically active units of endotoxin. J Biol Chem 2004; 279: 26307—26313.

42.

Caccavo D. , Afeltra A. , Pece S. et al. Lactoferrin-lipid A-lipopolysaccharide interaction: inhibition by anti-human lactoferrin monoclonal antibody AGM 10.14. Infect Immun 1999; 67: 4668—4672.

43.

Jiao B. , Freudenberg M. , Galanos C. Characterization of the lipid A component of genuine smooth-form lipopolysaccharide . Eur J Biochem 1989; 180: 515—518.

44.

Taylor AH , Heavner G. , Nedelman M. et al. Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein. J Biol Chem 1995; 270: 17934—17938.

45.

Hoess A. , Schneider-Mergener J. , Liddington RC , Identification of the LPS-binding domain of an endotoxin neutralising protein, Limulus anti-LPS factor. Prog Clin Biol Res 1995; 392: 327—337.

46.

Augusto LA , Li J. , Synguelakis M. , Johansson J. , Chaby R. Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide. J Biol Chem 2002; 277: 23484—23492.

47.

Elass E. , Masson M. , Mazurier J. , Legrand D. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycanbinding ability of interleukin-8 in human endothelial cells. Infect Immun 2002; 70: 1860—1866.

48.

Husson A. , Brasse-Lagnel C. , Fairand A. , Renouf S. , Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle . Eur J Biochem 2003; 270: 1887—1899.

49.

Wu G. , Morris Jr SM Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336: 1—17.

50.

Wu GY , Brosnan JT Macrophages can convert citrulline into arginine. Biochem J 1992; 281: 45—48.

51.

Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907—916.

52.

McCormick SM , Eskin SG , McIntire LV et al. DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc Natl Acad Sci USA 2001; 98: 8955—8960.

53.

Oyadomari S. , Gotoh T. , Aoyagi K. , Araki E. , Shichiri M. , Mori M. Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide 2001; 5: 252—260.

54.

Nagasaki A. , Gotoh T. , Takeya M. et al. Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analyses. J Biol Chem 1996; 271: 2658—2662.

55.

Flam BR , Hartmann PJ , Harrell-Booth M. , Solomonson LP , Eichler DC Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 2001; 5: 187—197.

56.

Abu-Absi SF , Friend JR , Hansen LK , Hu W-S. Structural polarity and functional bile canaliculi in rat hepatocyte spheroids. Exp Cell Res 2002; 274: 56—67.

57.

Saheki T. , Komorizono K. , Miura T. , Ichiki H. , Yagi Y. , Hashimoto S. Clearance of argininosuccinate synthetase from the circulation in acute liver disease. Clin Biochem 1990; 23: 139—141.